257 related articles for article (PubMed ID: 26685984)
1. Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma.
Adachi M; Hoshino Y; Izumi Y; Takagi S
J Vet Med Sci; 2016 May; 78(4):649-56. PubMed ID: 26685984
[TBL] [Abstract][Full Text] [Related]
2. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas.
Murai A; Abou Asa S; Kodama A; Sakai H; Hirata A; Yanai T
J Comp Pathol; 2012 Nov; 147(4):430-40. PubMed ID: 22789858
[TBL] [Abstract][Full Text] [Related]
4. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
[TBL] [Abstract][Full Text] [Related]
7. Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma.
Asa SA; Murai A; Murakami M; Hoshino Y; Mori T; Maruo K; Khater A; El-Sawak A; el-Aziz EA; Yanai T; Sakai H
Histol Histopathol; 2012 May; 27(5):601-7. PubMed ID: 22419024
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
9. Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma.
Spugnini EP; Esposito V; Groeger AM; Cassandro R; Onori N; Chirianni A; Baldi A
In Vivo; 2006; 20(1):125-7. PubMed ID: 16433040
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
[TBL] [Abstract][Full Text] [Related]
11. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
[TBL] [Abstract][Full Text] [Related]
12. Managing malignant disease in dogs.
Polton G
Vet Rec; 2009 Nov; 165(19):576. PubMed ID: 19897876
[No Abstract] [Full Text] [Related]
13. Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours.
Anwar Sh; Yanai T; Sakai H
J Comp Pathol; 2015 Nov; 153(4):278-82. PubMed ID: 26286429
[TBL] [Abstract][Full Text] [Related]
14. Big endothelin-1 as a tumour marker for canine haemangiosarcoma.
Fukumoto S; Miyasho T; Hanazono K; Saida K; Kadosawa T; Iwano H; Uchide T
Vet J; 2015 Jun; 204(3):269-74. PubMed ID: 25920760
[TBL] [Abstract][Full Text] [Related]
15. Chromatin run-on sequencing analysis finds that ECM remodeling plays an important role in canine hemangiosarcoma pathogenesis.
Mukai C; Choi E; Sams KL; Klampen EZ; Anguish L; Marks BA; Rice EJ; Wang Z; Choate LA; Chou SP; Kato Y; Miller AD; Danko CG; Coonrod SA
BMC Vet Res; 2020 Jun; 16(1):206. PubMed ID: 32571313
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
[TBL] [Abstract][Full Text] [Related]
17. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
18. Treatment of canine hemangiosarcoma: 2000 and beyond.
Clifford CA; Mackin AJ; Henry CJ
J Vet Intern Med; 2000; 14(5):479-85. PubMed ID: 11012108
[TBL] [Abstract][Full Text] [Related]
19. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
[TBL] [Abstract][Full Text] [Related]
20. A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs.
Grimes JA; Prasad N; Levy S; Cattley R; Lindley S; Boothe HW; Henderson RA; Smith BF
BMC Vet Res; 2016 Dec; 12(1):272. PubMed ID: 27912752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
